Drug Trial Radar · NCT07768345
A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
440
Planned (sponsor's estimate)
Start
Aug 31, 2026
Primary completion
Feb 2, 2028
Study completion Feb 2, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this phase 3 study is to learn the safety, tolerability and immunogenicity of revaccination with RSVpreF at approximately 1-, 2-, and 3-year intervals to inform the revaccination interval in immunocompromised adults. This study is seeking participants who are 18 years of age and older and will be grouped based on prior RSV vaccination history. Participants are required to be immunocompromised per study protocol. All participants in this study will receive 1 shot to their arm of a RSVPreF vaccine. Participants will take part in this study for about 12 months and will need to visit the clinical study site at least 4 times.
Conditions
- Respiratory Syncytial Virus (RSV)
Interventions
RSVpreF VaccineBiological
RSVpreF Vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants reporting local reactionsTime frame: For up to 7 days after vaccination
- Percentage of participants reporting systemic eventsTime frame: For up to 7 days after vaccination
- Percentage of participants reporting adverse eventsTime frame: Through 1 month after vaccination
- Percentage of participants reporting newly diagnosed chronic medical conditionsTime frame: Through 12 months after vaccination
- Percentage of participants reporting serious adverse eventsTime frame: Through 12 months after vaccination
- Neutralizing Titers (NTs) for RSV A and RSV B expressed as Geometric Mean Titer (GMT)Time frame: Before vaccination, 1 month, 6 months and 12 months after vaccination
- NTs for RSV A and RSV B expressed as Geometric Mean Fold Rise (GMFR)Time frame: Before vaccination, 1 month, 6 months and 12 months after vaccination
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Kaiser Foundation Hospital LAMC
Los Angeles, California · Recruiting
Kaiser Permanente Los Angeles Medical center
Los Angeles, California · Recruiting
Kaiser Permanente
Los Angeles, California · Recruiting
University of Colorado Anschutz Medical Campus - Vaccine and Clinical Trials Clinic
Aurora, Colorado · Recruiting
George Washington University
Washington D.C., District of Columbia · Recruiting
The Hope Clinic of Emory University
Decatur, Georgia · Recruiting
University of Iowa
Iowa City, Iowa · Recruiting
University of Iowa, Infectious Disease Research Laboratory, VA Medical Center
Iowa City, Iowa · Recruiting
Ochsner Clinic Foundation - Kenner Clinical Trials Unit
Kenner, Louisiana · Recruiting
University of Maryland, Institute of Human Virology
Baltimore, Maryland · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
University of Nebraska Medical Center/ Nebraska Medicine
Omaha, Nebraska · Recruiting
NYU Langone Health Vaccine Center
New York, New York · Recruiting
Rochester Clinical Research
Rochester, New York · Recruiting
University of Rochester Investigational Drug Services
Rochester, New York · Recruiting
University of Rochester Medical Center-Infectious Diseases Research Clinic
Rochester, New York · Recruiting
Duke Vaccine and Trials Unit
Durham, North Carolina · Recruiting
Duke Clinics 2F, 2G
Durham, North Carolina · Recruiting
Altoona Center for Clinical Research
Duncansville, Pennsylvania · Recruiting
Epic Medical Research-Desoto
DeSoto, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.